Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 14, Issue 8, Pages 2012-2015Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2018.1461300
Keywords
interleukin-22; interleukin-1; cancer immunotherapy
Categories
Funding
- international doctoral program i-Target: Immunotargeting of cancer - Elite Network of Bavaria
- Melanoma Research Alliance [409510]
- Marie-Sklodowska-Curie Training Network for the Immunotherapy of Cancer (IMMUTRAIN) - H2020 program of the European Union
- Else Kroner-Fresenius-Stiftung
- German Cancer Aid
- Ernst-Jung-Stiftung
- LMU Munich's Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
- Bundesministerium fur Bildung und Forschung VIP+ grant ONKATTRACT
- European Research Council [756017]
Ask authors/readers for more resources
Interleukin-22 (IL-22) is a member of IL-10 family of cytokines. IL-22 induces proliferative and anti-apoptotic signaling pathways and production of anti-microbial molecules that enhance tissue regeneration and host defense. IL-22 has also been identified as a cancer-promoting cytokine since deregulation of the IL-22-IL-22R1 system is linked to different cancer entities including lung, breast, gastric, pancreatic and colon cancers. T cells and innate lymphoid cells are the main cellular sources of IL-22. Expression of its specific receptor IL-22R1 is restricted to the non-hematopoietic cells which makes the IL-22-IL-22R1 pathway an attractive target for anti-cancer therapy. For development of such therapies, a better understanding of IL-22 regulation in the tumor microenvironment is needed. We could recently decipher how cancer cells promote IL-22 production by memory T cells via induction of IL-1. Here we will discuss how this knowledge might contribute to developing therapies disregulating the IL-22 pathway for cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available